Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - salmeterol; fluticasone propionate - inhalation powder, pre-dispensed - 50 microg/250 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - salmeterol; fluticasone propionate - inhalation powder, pre-dispensed - 50 microg/500 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

lexon pharmaceuticals (ireland) limited - salmeterol xinafoate; fluticasone propionate - inhalation powder, pre-dispensed - 50/500 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

lexon pharmaceuticals (ireland) limited - salmeterol; fluticasone propionate - inhalation powder, pre-dispensed - 50/250 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluconazole, quantity: 100 mg - capsule, hard - excipient ingredients: patent blue v; colloidal anhydrous silica; titanium dioxide; sodium lauryl sulfate; magnesium stearate; gelatin; lactose monohydrate; maize starch; erythrosine; butan-1-ol; shellac; industrial methylated spirit; dimeticone 1510; iron oxide black; lecithin; propylene glycol; isopropyl alcohol; purified water; ethanol; strong ammonia solution; potassium hydroxide - indications as at 21 june 2005 : diflucan, given orally, is indicated for: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note : data suggest that the clinical efficacy of diflucan is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. 3. treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note : it remains to be shown that diflucan is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. 6. vaginal candidiasis when topical therapy has failed. 7. treatment of exten

United States - English - NLM (National Library of Medicine)

roerig - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole 50 mg - diflucan (fluconazole) is indicated for the treatment of: diflucan is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. diflucan (fluconazole) is contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. there is no information regarding cross-hypersensitivity between fluconazole and other azole antifungal agents. caution should be used in prescribing diflucan to patients with hypersensitivity to other azoles. coadministration of other drugs known to prolong the qt interval and which are metabolized via the enzyme cyp3a4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (see clinical pharmacology: drug interaction studies and precautions .)

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole 200 mg - diflucan (fluconazole) is indicated for the treatment of: - vaginal candidiasis (vaginal yeast infections due to candida ). - oropharyngeal and esophageal candidiasis. in open noncomparative studies of relatively small numbers of patients, diflucan was also effective for the treatment of candida urinary tract infections, peritonitis, and systemic candida infections including candidemia, disseminated candidiasis, and pneumonia. - cryptococcal meningitis. before prescribing diflucan (fluconazole) for aids patients with cryptococcal meningitis, please see clinical studies section. studies comparing diflucan to amphotericin b in non-hiv infected patients have not been conducted. diflucan is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology, histopathology)